Friday, July 10, 2026
🇺🇸 FDA

Drug profile · INN

mitapivat

PYRUKYND

mitapivat (PYRUKYND) is a pyruvate kinase isozymes r/l activator. Associated with Agios Netherlands B.V..

EMA: approved Blood and blood forming organs (B06) B06AX04
Patents linked 20
Pipeline programs 18
News articles 0
Drug details — mitapivat
Class
Blood and blood forming organs (B06)
Route
—
Patents
20
Programs
18
Data quality
0.89
← All drugs Manufacturer profile Related patents Pipeline programs Drug news hub Event calendar

Quick answer

mitapivat (PYRUKYND) is a pyruvate kinase isozymes r/l activator. Associated with Agios Netherlands B.V..

Key facts

INN mitapivat
Brand PYRUKYND
Mechanism Pyruvate kinase isozymes R/L activator
Target Pyruvate kinase PKLR
Therapeutic class Blood and blood forming organs (B06)
ATC code B06AX04
Originator Agios Netherlands B.V.

Mechanism of action

Pyruvate kinase isozymes R/L activator

Primary target: Pyruvate kinase PKLR

Approval history

Authority Status Date
EMA approved —

Pipeline programs

Search pipeline Sponsor programs
  1. AG348-C-020 Phase 3 · Anaxis Pharma · Anemia in subjects with sickle cell disease (SCD)
  2. AG348-C-022 Phase 3 · Anaxis Pharma · Pyruvate Kinase Deficiency
  3. AG348-C-023 Phase 3 · Anaxis Pharma · Pyruvate Kinase Deficiency
  4. MITAPIVAT, Placebo for Mitapivat Phase 3 · Anaxis Pharma · Transfusion-Dependent Alpha- or Beta-Thalassemia
  5. Mitapivat Phase 3 · Agios Netherlands · Non-Transfusion-dependent Alpha-Thalassemia
  6. Mitapivat Phase 3 · Agios Netherlands · Pediatric Pyruvate Kinase Deficiency
  7. Mitapivat Phase 3 · Agios Netherlands · Sickle Cell Disease
  8. Mitapivat Matched Placebo Phase 3 · Agios Netherlands · Transfusion-dependent Alpha-Thalassemia

Related & competitor drugs

Browse all drugs
  1. apixaban Blood and blood forming organs (B01)
  2. berotralstat Blood and blood forming organs (B06)
  3. bivalirudin Blood and blood forming organs (B01)
  4. c1 inhibitor (human) Blood and blood forming organs (B06)
  5. clopidogrel Blood and blood forming organs (B01)
  6. dabigatran etexilate Blood and blood forming organs (B01)

Related patents

Browse patents Agios Netherlands B.V. patent hub

  1. US 12428376

    Therapeutic compounds and compositions

    Expires Mon Sep 25 2045 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  2. US 12133853

    Pyruvate kinase activators for use in treating blood disorders

    Expires Mon Oct 31 2044 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  3. US 11957680

    Pyruvate kinase activators for use in treating blood disorders

    Expires Mon Apr 11 2044 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  4. US 11919915

    Compounds and methods useful for stabilizing phenylalanine hydroxylase mutations

    Expires Mon Feb 29 2044 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  5. US 11878049

    Mitapivat therapy and modulators of cytochrome P450

    Expires Mon Jan 18 2044 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  6. US 11872225

    Pyruvate kinase modulators and use thereof

    Expires Mon Jan 11 2044 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  7. US 11866411

    Therapeutic compounds and compositions

    Expires Mon Jan 04 2044 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  8. US 11590132

    Pyruvate kinase activators for use in treating blood disorders

    Expires Mon Feb 23 2043 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  9. US 11464775

    Pyruvate kinase modulators and use thereof

    Expires Mon Oct 06 2042 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  10. US 11364240

    Pyruvate kinase activators for use in treating blood disorders

    Expires Mon Jun 16 2042 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  11. US 11040036

    Pyruvate kinase activators for use in treating blood disorders

    Expires Mon Jun 17 2041 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  12. US 11021515

    Therapeutically active compounds and their methods of use

    Expires Mon May 27 2041 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  13. US 10988448

    Therapeutic compounds and compositions

    Expires Mon Apr 22 2041 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  14. US 10946023

    Therapeutically active compounds and their methods of use

    Expires Mon Mar 11 2041 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  15. US 10730854

    Therapeutically active compounds and their methods of use

    Expires Mon Jul 30 2040 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  16. US 10689375

    Compounds and their methods of use

    Expires Mon Jun 18 2040 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  17. US 10689414

    Therapeutically active compounds and their methods of use

    Expires Mon Jun 18 2040 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  18. US 10640534

    Therapeutically active compositions and their methods of use

    Expires Mon Apr 30 2040 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  19. US 10434105

    Therapeutically active compounds and their methods of use

    Expires Mon Oct 03 2039 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  20. US 10201543

    Therapeutically active compounds and their methods of use

    Expires Mon Feb 07 2039 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

Frequently asked questions

What is mitapivat?

mitapivat (PYRUKYND) is a pyruvate kinase isozymes r/l activator. Associated with Agios Netherlands B.V..

What is the brand name for mitapivat?

PYRUKYND is a marketed brand name for mitapivat. Check FDA Drugs@FDA for the current US label holder and prescribing information.

Drug approvals, clinical trials, M&A, event intelligence, and company updates — weekly.

Customize topics & region
Topics
Region

No spam. Unsubscribe anytime. See our privacy policy.